Compare RLX Technology Inc (RLX) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
RLX Technology Inc vs Summit Therapeutics Inc — how do they compare? RLX Technology Inc trades at $2.03 (market cap $2.52B), while Summit Therapeutics Inc trades at $14.58 (market cap $10.48B). The key difference: Summit Therapeutics Inc is far larger — about 4.2× RLX Technology Inc's market cap, and RLX Technology Inc pays a 4.85% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| RLX | SMMT | |
|---|---|---|
Market Cap | $2.52B | $10.48B |
Sector | Technology | Health |
52-Week High | $2.73 | $29.32 |
52-Week Low | $1.79 | $13.05 |
Enterprise Value | $1.15B | $9.90B |
Dividend Yield | 4.85% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RLX trades at $2.06, up 0.49% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported Q1 2026 revenue growth driven by international expansion, with 2025 net income of $921.87M and a net margin of 22.47%. Recent news highlights the company's cash-rich, debt-free position and its positioning in the growing global vaping market.
The outlook is mixed; strong fundamentals and market growth potential are offset by consecutive earnings misses and a single analyst's hold rating. Key risks include regulatory scrutiny in the vaping industry and execution challenges in international expansion. The stock presents a speculative opportunity for investors comfortable with sector-specific regulatory risks.
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.
The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
